ASX-173

Overview

ASX-173 is an orally active inhibitor of asparagine synthetase (ASNS) ( IC 50 = 0.113 μM, K i = 0.4 nM). ASX-173 enhances the anticancer activity of L-asparaginase (ASNase) ( HY-P1923 ). ASX-173 disrupts nucleotide synthesis and induces leukemia cell cycle arrest, apoptosis and autophagy in leukemia cells in combination with ASNase. ASX-173 slows the growth of OCI-AML2 xenografts in combination with ASNase. ASX-173 is indicated for the study of acute lymphoblastic leukemia, acute myeloid leukemia, colorectal cancer , and other cancers.

Application

Products | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Autophagy | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PARP | Products > Signaling Pathways > Akt | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Atg8/LC3 | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Caspase | Products > Signaling Pathways > CDK

Product Information

• Catalog No.: HY-175282
• CAS No.: 2748800-08-8
• Molecular Formula: C28H30FN3O3
• Molecular Weight: 475.55
• Purity: 98.47%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (5.26 mM); Clear solution
• Availability: In-stock

Source

Original product source